Cargando…

Cyclosporine A and COVID-19 – The COQUIMA cohort

Detalles Bibliográficos
Autores principales:	Schuurmans, Macé M., Hage, René
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772530/ https://www.ncbi.nlm.nih.gov/pubmed/33385129 http://dx.doi.org/10.1016/j.eclinm.2020.100680

Ejemplares similares

Cyclosporine A and COVID19 – The COQUIMA cohort
por: Sánchez-Pernaute, Olga
Publicado: (2020)

Cyclosporine A and COVID19 – The COQUIMA cohort – Author's reply
por: Guisado-Vasco, Pablo, et al.
Publicado: (2020)

Calcineurin Inhibitors and COVID-19
por: Hage, René, et al.
Publicado: (2022)

Calcineurin Inhibitors and COVID-19
por: Hage, René, et al.
Publicado: (2022)

Calcineurin inhibitors revisited: A new paradigm for COVID-19?
por: Hage, René, et al.
Publicado: (2020)

Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
por: Guisado-Vasco, Pablo, et al.
Publicado: (2020)

COVID-19-related end stage lung disease: two distinct phenotypes
por: Kostopanagiotou, Kostantinos, et al.
Publicado: (2022)

Suggested management of e-cigarette or vaping product use associated lung injury (EVALI)
por: Hage, René, et al.
Publicado: (2020)

Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
por: Hage, René, et al.
Publicado: (2021)

Adaptive Immunosuppression in Lung Transplant Recipients Applying Complementary Biomarkers: The Zurich Protocol
por: Schuurmans, Macé M., et al.
Publicado: (2023)

P137 COVID-19 in cystic fibrosis patients with and without lung transplantation: the Zurich cohort
por: Steinack, C., et al.
Publicado: (2021)

Impact of SARS-CoV-2-Related Hygiene Measures on Community-Acquired Respiratory Virus Infections in Lung Transplant Recipients in Switzerland
por: Baumann, Isabelle, et al.
Publicado: (2023)

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
por: Sanchez-Pernaute, Olga, et al.
Publicado: (2021)

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
por: Sanchez-Pernaute, Olga, et al.
Publicado: (2021)

No Association Between Cyclosporine Levels and Dyslipidemia?
por: Filler, Guido
Publicado: (2014)

Dyslipidemia in Renal Transplant Recipients Treated With Cyclosporine A
por: Niemczyk, Mariusz
Publicado: (2013)

Cyclosporine-induced childhood generalized hypertrichosis()()
por: Souza, Karilena Fernandes, et al.
Publicado: (2020)

Cosmetically Disfiguring Side Effects of Cyclosporine
por: Panicker, Vinitha Varghese, et al.
Publicado: (2012)

Cyclosporine Effects on Pediatric Kidney Recipients
por: Hami, Maryam
Publicado: (2012)

Transbronchial Cryobiopsy Compared to Forceps Biopsy for Diagnosis of Acute Cellular Rejection in Lung Transplants: Analysis of 63 Consecutive Procedures
por: Steinack, Carolin, et al.
Publicado: (2022)

Triage tool for suspected COVID-19 patients in the emergency room: AIFELL score
por: Levenfus, Ian, et al.
Publicado: (2020)

Monitoring Cyclosporine Absorption: A Step Beyond Therapeutic Drug Monitoring
por: Lee, Po-Chang
Publicado: (2012)

Multimodal Remote Home Monitoring of Lung Transplant Recipients during COVID-19 Vaccinations: Usability Pilot Study of the COVIDA Desk Incorporating Wearable Devices
por: Schuurmans, Macé M., et al.
Publicado: (2023)

Bioequivalence study of cyclosporine in renal transplant recipients
por: Gautam, Gagan
Publicado: (2007)

Effect of Erdosteine on Cyclosporine Induced Chronic Nephrotoxicity
por: Briguori, Carlo, et al.
Publicado: (2012)

Lichen striatus successfully treated with oral cyclosporine
por: Romita, Paolo, et al.
Publicado: (2017)

Cyclosporine A at Reperfusion Reduces Infarct Size in Pigs
por: Skyschally, Andreas, et al.
Publicado: (2010)

Monitoring of Cyclosporine A Blood Levels in Clinical Settings
por: Niemczyk, Mariusz
Publicado: (2012)

Cyclosporine has a potential role in the treatment of SARS
por: Russell, Clark D., et al.
Publicado: (2013)

Cyclosporine therapy during the COVID-19 pandemic
por: Rudnicka, Lidia, et al.
Publicado: (2020)

Dyslipidemia After Kidney Transplantation and Correlation With Cyclosporine Level: A Glimpse into the Future
por: Ahmed, Mohamed H.
Publicado: (2013)

A phase I trial of cyclosporine for hospitalized patients with COVID-19
por: Blumberg, Emily A., et al.
Publicado: (2022)

Gingival enlargement due to Cyclosporine A therapy in aplastic anaemia
por: Sabnis, Girish R., et al.
Publicado: (2011)

Insights into the Possible Mechanism of Cyclosporine-Induced Chronic Nephrotoxicity; Arteriolopathy
por: Yoon, Sang Pil
Publicado: (2012)

Still the Joker in the Pack: When to Take Out Cyclosporine in the Game?
por: Resál, Tamás, et al.
Publicado: (2021)

Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?
por: Devaux, Christian A., et al.
Publicado: (2021)

Is the interaction between ticlopidine and cyclosporin dose related? Report of three cases
por: Houssaïni, Tarik Sqalli, et al.
Publicado: (2010)

A Pediatric Patient with Intravenous Cyclosporine Anaphylaxis Who Tolerated the Oral Form
por: Işık, Pamir, et al.
Publicado: (2014)

Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient with Pemphigus Vulgaris
por: Park, So Eun, et al.
Publicado: (2015)

Use of Cyclosporine Therapy in Dermatology During COVID-19 Pandemic
por: Pathania, Y.S.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h5qmop8rvotimls16mnb8ishq5